- Home
- NWAX vs RLMD Comparison
NWAX vs RLMD Comparison
Compare NWAX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWAX | RLMD |
|---|---|---|
| Founded | 2025 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.5M | 461.9M |
| IPO Year | 2025 | 2012 |
Fundamental Metrics
Financial Performance| Metric | NWAX | RLMD |
|---|---|---|
| Price | $10.03 | $3.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 175.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $9.68 | $2.15 |
| 52 Week High | $10.34 | $8.00 |
Technical Indicators
Market Signals| Indicator | NWAX | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 30.55 | 39.37 |
| Support Level | $10.00 | $3.13 |
| Resistance Level | $10.17 | $3.55 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 20.00 | 41.65 |
Price Performance
Historical ComparisonAbout NWAX New America Acquisition I Corp. Class A Common Stock
New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.